Last reviewed · How we verify
Benralizumab Arm A
Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduction of eosinophilic inflammation.
Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduction of eosinophilic inflammation. Used for Severe eosinophilic asthma, Chronic rhinosinusitis with nasal polyps (eosinophilic phenotype), Eosinophilic granulomatosis with polyangiitis (EGPA).
At a glance
| Generic name | Benralizumab Arm A |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | IL-5 receptor antagonist monoclonal antibody |
| Target | IL-5 receptor alpha (CD125) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Benralizumab targets the IL-5 receptor alpha (CD125) expressed on eosinophils and basophils, blocking IL-5 signaling and triggering antibody-dependent cellular cytotoxicity (ADCC) to eliminate these cells. This mechanism reduces eosinophilic inflammation in the airways and tissues, making it effective for eosinophil-driven inflammatory diseases. The drug is particularly useful in conditions characterized by elevated eosinophil counts.
Approved indications
- Severe eosinophilic asthma
- Chronic rhinosinusitis with nasal polyps (eosinophilic phenotype)
- Eosinophilic granulomatosis with polyangiitis (EGPA)
Common side effects
- Headache
- Nasopharyngitis
- Injection site reactions
- Pyrexia
Key clinical trials
- This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
- Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment (PHASE3)
- Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment (PHASE3)
- A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) (PHASE3)
- Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. (PHASE3)
- STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma (PHASE3)
- Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study) (PHASE3)
- Patient-reported Outcomes in Real-world Use of Benralizumab in Patients With Severe Eosinophilic Asthma in Belgium
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Benralizumab Arm A CI brief — competitive landscape report
- Benralizumab Arm A updates RSS · CI watch RSS
- AstraZeneca portfolio CI